Congratulations to ANZSA Board Member Dr Vivek Bhadri on his induction into the @myESMO Faculty!
From 2026–2030, he will serve on the Sarcoma Faculty Group, as the only Australian representative championing sarcoma care and education.
This #InternationalWomenAndGirlsInScienceDay, we’re proud to spotlight a conversation between Prof @AngelaHong (Deputy Chair, ANZSA) and Dr Cui Tu (Maxine), our 2025 Sarcoma Research Grant recipient.
Read their conversation: https://t.co/FkhaaJ7CoM
🧬 Cell therapy in #sarcoma: what do we know so far?
In our review in @jitcancer we cover
✔️TCR-T, CAR-T, TIL, NK-cell approaches
✔️Early clinical studies
✔️Key biological & practical challenges, inc. the tumour microenvironment
✔️Emerging directions
🔗 https://t.co/q768GoVKo8
The FLORRAL study continues to build momentum, increasing to 12 participating sites nationally and internationally with a total of 96 patients data collected to date. A major international effort to improve outcomes for retroperitoneal sarcoma patients!
#retroperitoneal#sarcoma
Last week, ANZSA attended the @ctosociety Annual Meeting, connecting with international sarcoma leaders to share knowledge and advance research.
Highlight: @DrLizConnolly was elected to the CTOS Board of Directors- congratulations Liz!
#CTOS2025
Welcome to our newly appointed ANZSA Board Directors!
A/Prof Richard Boyle (RPA Hospital) & Andy Johnston (Auckland City Hospital) bring world-class expertise in sarcoma care, orthopaedics & research to guide ANZSA’s mission.
@CNSA_ORG CEO Jemma Still talks with @DrLizConnolly and sarcoma nurse Emma Gardner about the complexities of sarcoma and the crucial role nurses play in patient care. Listen to the full conversation: https://t.co/ah5N57KDWa
Final day of #ANZSAASM2025 in Hobart wrapped with big energy—AI in sarcoma care, patient-reported outcomes, palliative integration, AYA needs, lived experience and the Great Debate on regional vs centre-based care. Congrats to Barnaby Kelly on best poster!
Kicking off #ANZSAASM2025 with a warm welcome from Fiona Maclean and opening remarks by Tasmanian Senator Wendy Askew. Our wonderful Consumer Advisor, Natalia Dewiyani, shared plenty of hugs and delivered a beautiful opening speech.
We’ve arrived in Hobart!
To kick things off, the ANZSA Scientific Advisory Committee is meeting to discuss recent research developments and explore future directions.
It’s wonderful to see sarcoma specialists and consumers from across Australia and New Zealand collaborating.
ASM is so close!
One of the most anticipated speakers is Prof Jason Yustein, pediatric oncologist and physician-scientist from Children’s Healthcare of Atlanta.
To download the program, visit: https://t.co/Ii5DbE7mnn
Attend online or in person visit: https://t.co/Au7WrFEOXY
Thank you to our Board Director, Dr @VivekBhadri and our Scientific Advisor, A/Prof Jeremy Lewin for contributing their expertise to our 2025 Sarcoma Awareness Month campaign through their interview with Australian Health Journal.
MISSION TO RAISE AWARENESS OF SARCOMA AND CLINICAL TRIAL FUNDING Research lagging for sarcoma, despite accounting for one third of adolescent cancer deaths
With
Associate Professor Jeremy Lewin, Medical Oncologist,
Peter MacCallum Cancer Centre & Medical Director,
Victorian Adolescent and Young Adult Cancer Service &
Research & Education Lead - Sarcoma, VCCC Alliance @VCCCAlliance
Dr Vivek Bhadri @VivekBhadri ,
Paediatric and Adolescent Medical Oncologist
Chris O'Brien Lifehouse @COBLH & Westmead Public Hospital @WestSydHealth &
Board Director
Australia and New Zealand Sarcoma Association (ANZSA) @anzsarcoma
AUSTRALIAN HEALTH JOURNAL SEGMENT
Filmed in Sydney & Melbourne | September 2025
Sarcoma, a rare and aggressive cancer, remains the deadliest cancer for children and young adults, accounting for nearly one third (30%) of cancer-related deaths among those aged 15–24 and one tenth (10%) of those aged 0–14. Further, still severely under-diagnosed, sarcoma only accounts for one sixth (15%) of all cancer diagnoses in the 15 – 24 age group, and less than a tenth (8%) among children under 10.
Despite this, public awareness and research funding for sarcoma funding remain critically low, with sarcoma receiving just $4.6m in funding for research in 2018-2020 – compared to the tens of millions other cancers receive. Sarcoma gets only a tiny fraction of funding for research that more common cancers receive, despite having the same costs to conduct studies.
The lack of funding reflects long-term survival rates for sarcoma which remain concerningly low, at just a 50% 10-year survival rate, while five-year survival rates for common cancers such as prostate and breast cancer have increased to over 90% in the past four decades (96% and 92% respectively).
Accounting for just 1% of all adult cancer diagnoses, sarcomas are rare and complex cancers that form in bone, cartilage or soft tissue8. There are over 100 different subtypes of sarcoma, which each require their own diagnostic and treatment pathways, which is why continued research is essential to improving patient outcomes.
Research indicates sarcomas are misdiagnosed in nearly one third (30%) of cases, emphasising the importance of ongoing research to support diagnostic developments, alongside improvements in patient treatment and management pathways.
Source: Australian and New Zealand Sarcoma Association (ANZSA) media release 1 July 2025
Australian Health Journal @AUHealthJournal
Produced & published by AUDIENCED
Get your interviews captured across Australia https://t.co/mlk5MPl9oY
🚨 Our ASM is only a few months away!
We will gather in Hobart to share expertise, foster collaboration, and drive innovation in sarcoma care and research.
2025 Theme: "United Against Sarcoma: Collaboration and Innovation."
Register today: https://t.co/tVVPVjT8AV
Abstract submissions due tomorrow by MIDNIGHT (AEST)! Join us under the theme Collaboration & Innovation.
Kudos to 2024 Poster Prize winner Jacqui McGovern for her inspiring work—your poster could be next.
Submit here: https://t.co/LjsB9ifXRW
📢 1 Week Left to Submit Your Abstract
There’s just 1 week remaining to submit your abstract for the 2025 ASM.
Abstract/poster submissions must be received electronically via the online form by midnight (AEST) on Friday 1 August 2025.
Submit: https://t.co/P1dspirmbU
Today our wonderful Deputy Chair, Professor @AngelaHong, lead her GenesisCare Plank-a-thon team in Sydney for sarcoma research!
To sign up or show your support, please visit https://t.co/YjsSJLBjeX
#sarcomaawareness#research#teamspirit
Calling all researchers.
Showcase your work at the 2025 ANZSA ASM and help shape the future of sarcoma care. Share your findings with a multidisciplinary audience committed to innovation.
Abstract submissions are now open- Don't miss out!
Submit here: https://t.co/LjsB9ifXRW
📢 The Provisional Program for the ANZSA Annual Scientific Meeting is now available.
Take a look at the planned sessions and speakers, and don’t forget to register to attend.
View the program here: https://t.co/Ii5DbE7mnn